New drug combo aims to shrink metastatic kidney tumors

NCT ID NCT01038778

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times

Summary

This study tests whether adding entinostat to high-dose aldesleukin (interleukin-2) can help shrink tumors in people with metastatic kidney cancer. About 47 adults with clear cell renal cell carcinoma that has spread will receive both drugs. The goal is to find the safest dose and see how many patients respond to treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
entinostat and aldesleukin (interleukin-2)
What this could lead to
If it works, this combination could offer a new treatment option for people with advanced kidney cancer that has spread.
What could go wrong
This is an early-phase trial with only 47 participants, so results may not apply to everyone. The drugs can cause serious side effects, and the combination may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland, 21287, United States

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio, 43210, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California, 90033, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.